<ol>
    <li>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein
        thrombosis and pulmonary embolism: a population-based case-control study. <em>Arch Intern Med</em>.
        2000;160:809-815.</li>
    <li>Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous
        thrombosis. <em>JAMA</em>. 2005;293:715-722.</li>
    <li>Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study
        using linked United Kingdom databases. <em>Eur J Cancer</em>. 2013;49:1404-1413.</li>
    <li>Cronin-Fenton DP, SÃ¸ndergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer
        patients and the general population: a population-based cohort study in Denmark, 1997-2006. <em>Br J Cancer</em>.
        2010;103:947-953.</li>
    <li>Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. <em>Blood</em>.
        2013;122:1712-1723.</li>
    <li>Kearon C,
        Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of
        Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <em>Chest.
        </em>2012;141(2 suppl):e419S-e496S.</li>
    <li>Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel
        Report. <em>Chest</em>. 2016;149:315-352.</li>
    <li>Lyman GH, Bohlke K, Falanga A, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer:
        American Society of Clinical Oncology clinical practice guideline update. <em>J Oncol Pract</em>.
        2015;11:e442-e444.</li>
    <li>Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with
        anticoagulant treatments for cancer-associated thrombosis. <em>Res Pract Thromb Haemost</em>. 2017;1:14-22.</li>
    <li>Lyman GH, Eckert L, Wang Y, et al. Venous thromboembolism risk in patients with cancer receiving chemotherapy:
        a real-world analysis. <em>Oncologist</em>. 2013;18:1321-1329.</li>
    <li>Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism.
        <em>N Engl J Med. </em>2018;378:615-624.</li>
    <li>Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight
        heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). <em>J.
            Clin Oncol</em>. 2018;36:2017-2023.</li>
    <li>Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus dalteparin for the treatment of acute venous
        thromboembolism in patients with cancer: the Caravaggio study. <em>Thromb Haemost</em>.
        2018. [Epub ahead of print].</li>
    <li>van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with
        cancer. Rationale and design of the Hokusai VTE-cancer study. <em>Thromb Haemost.</em> 2015;114:1268-1276.</li>
    <li>Young A, Phillips J, Hancocks H, et al. OC-11 -- Anticoagulation therapy in selected cancer patients at risk of
        recurrence of venous thromboembolism. <em>Thromb Res.</em> 2016;140:S172-S173.</li>
    <li>Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous
        thromboembolism: results from the Hokusai VTE Cancer Study. <em>Thromb Haemost</em>. 2018;118:1439-1449.</li>
    <li>Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated
        venous thromboembolism: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018. [Epub ahead of
        print].</li>
    <li>Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with
        thrombocytopenia: guidance from the SSC of the ISTH. <em>J Thromb Haemost</em>. 2018;16:1246-1249.</li>
    <li>Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the
        prevention and treatment of cancer-associated venous thromboembolism. <em>J Thromb Thrombolysis</em>.
        2016;41:81-91.</li>
    <li>Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk
        ambulatory patients with cancer: rationale and design of the CASSINI trial. <em>Thromb Haemost</em>.
        2017;117:2135-2145.</li>
    <li>Kimpton M, Wells PS, Carrier M. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory
        cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <em>Thromb Res</em>.
        2018;164:S124-S129.</li>
</ol>